Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Class A Common Stock, $0.0001 par value per share
-
Shares outstanding
-
99,823,000
-
Number of holders
-
38
-
Total 13F shares, excl. options
-
6,458,632
-
Shares change
-
+2,849,243
-
Total reported value, excl. options
-
$3,319,783
-
Value change
-
+$1,060,111
-
Put/Call ratio
-
0%
-
Number of buys
-
10
-
Number of sells
-
-13
-
Price
-
$0.5139
Significant Holders of Rani Therapeutics Holdings, Inc. - Class A Common Stock, $0.0001 par value per share (RANI) as of Q2 2025
47 filings reported holding RANI - Rani Therapeutics Holdings, Inc. - Class A Common Stock, $0.0001 par value per share as of Q2 2025.
Rani Therapeutics Holdings, Inc. - Class A Common Stock, $0.0001 par value per share (RANI) has 38 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6,458,632 shares
of 99,823,000 outstanding shares and own 6.5% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (3,151,354 shares), VANGUARD GROUP INC (799,679 shares), Nan Fung Group Holdings Ltd (493,584 shares), UNITED SERVICES AUTOMOBILE ASSOCIATION (302,743 shares), TAKEDA PHARMACEUTICAL CO LTD (203,190 shares), GEODE CAPITAL MANAGEMENT, LLC (190,557 shares), KESTRA PRIVATE WEALTH SERVICES, LLC (156,140 shares), CITADEL ADVISORS LLC (137,349 shares), BlackRock, Inc. (118,652 shares), and NORTHERN TRUST CORP (102,911 shares).
This table shows the top 38 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.